# US 6,730,480 B1 · Sphingosine kinase enzyme

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,480 B1
- Document ID: US6730480B1
- Status: Granted
- Kind: B1
- Application number: 09/959,897
- Filed: 2002-01-24
- Granted: 2004-05-04
- Earliest claimed: 1999-05-13
- Assignees: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Inventors: Stuart Maxwell Pitson; Brian Wolff Wattenberg; Pu Xia; Richard James D'Andrea; Jennifer Ruth Gamble; Matthew Alexander Vadas
- Web page: https://patentgrep.com/patent/US6730480B1

## CPC

- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic application.

## Claims

### Claim 1

An isolated polynucleotide encoding a sphingosine kinase, the polyinucleotide comprising (1) the sequence of SEQ ID NO:1, (2) a sequence at least 90% identical to SEQ ID NO:1, (3) a nucleotide sequence that hybridizes to the nucleotide sequence of (1) or (2) under high stringency conditions of about 65° C. and about 50% v/v formamide and about 0.15M salt, (4) a nucleotide sequence encoding a polypeptide having the sequence of SEQ ID NO:2, or (5) a nucleotide sequence complementary to the nucleotide sequence of any one of (1) to (4).

### Claim 2 (depends on 1)

An isolated polynucleotide according to claim 1, the polynucleotide comprising a sequence at least 95% identical to SEQ ID NO:1.

### Claim 3 (depends on 2)

An isolated polynucleotide sequence that hybridizes to the nucleotide sequence of claim 2 stringency conditions of about 65° C. and about 50% v/v formamide and about 0.15M salt.

### Claim 4 (depends on 1)

An isolated polynucleotide according to claim 1, the polynucleotide encoding a polypeptide having the sequence of SEQ ID NO:2.

### Claim 5 (depends on 1)

An isolated polynucleotide according to claim 1, the polynucleotide comprising the sequence of SEQ ID NO:1.

### Claim 6 (depends on 1)

An expression system comprising a polynucleotide according to claim 1.

### Claim 7 (depends on 6)

An expression system according to claim 6 capable of producing a sphingosine kinase comprising the polypeptide sequence of SEQ ID NO:2 when the expression system is in a compatible host cell.

### Claim 8 (depends on 7)

A recombinant host cell, the host cell comprising the expression system according to claim 7.

### Claim 9 (depends on 1)

A method of modulating expression of sphingosine kinase, in a subject, said method comprising
contacting the sphingosine kinase encoding gene with an effective amount of an agent for a time and under conditions sufficient to modulate expression of sphingosine kinase, said agent comprising an isolated polynucleotide according to claim 1.
